H.C. Wainwright Reiterates a Hold Rating on Evoke Pharma (EVOK)

By Carrie Williams

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Evoke Pharma (EVOKResearch Report). The company’s shares closed last Monday at $1.66.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.6% and a 43.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Evoke Pharma has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

Based on Evoke Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1.63 million. In comparison, last year the company had a GAAP net loss of $1.52 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.